PULM - Pulmatrix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.4622
+0.0012 (+0.2603%)
As of 10:23AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.4610
Open0.4800
Bid0.4600 x 600
Ask0.4699 x 1000
Day's Range0.4545 - 0.4800
52 Week Range0.4230 - 3.4200
Volume304,522
Avg. Volume813,812
Market Cap18.599M
Beta3.63
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is Pulmatrix Inc (NASDAQ:PULM) A Financially Sound Company?
    Simply Wall St.2 months ago

    Is Pulmatrix Inc (NASDAQ:PULM) A Financially Sound Company?

    Investors are always looking for growth in small-cap stocks like Pulmatrix Inc (NASDAQ:PULM), with a market cap of US$31.15M. However, an important fact which most ignore is: how financially healthyRead More...

  • Is Pulmatrix Inc (NASDAQ:PULM) Undervalued?
    Simply Wall St.3 months ago

    Is Pulmatrix Inc (NASDAQ:PULM) Undervalued?

    Pulmatrix Inc (NASDAQ:PULM), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGM over the last few months. As aRead More...

  • Zacks Small Cap Research3 months ago

    PULM: MHRA Authorizes CTA; Patient Screening Commences!

    By Anita Dushyanth, PhD NASDAQ:PULM Pulmatrix (NASDAQ:PULM) management filed a Clinical Trial Application (CTA) in 2H 2017 in the EU to support a Phase 1/1b trial in healthy volunteers and asthmatics, ...

  • How Pulmatrix Inc’s (NASDAQ:PULM) EPS Dropped 13.7%, Did Its Industry Show Weakness Too?
    Simply Wall St.4 months ago

    How Pulmatrix Inc’s (NASDAQ:PULM) EPS Dropped 13.7%, Did Its Industry Show Weakness Too?

    Examining Pulmatrix Inc’s (NASDAQ:PULM) past track record of performance is a useful exercise for investors. It allows us to reflect on whether the company has met or exceed expectations, whichRead More...

  • Pulmatrix Inc (PULM): Time For A Financial Health Check
    Simply Wall St.5 months ago

    Pulmatrix Inc (PULM): Time For A Financial Health Check

    While small-cap stocks, such as Pulmatrix Inc (NASDAQ:PULM) with its market cap of USD $34.31M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...

  • Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube5 months ago

    Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Pulmatrix, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Pulmatrix, Inc. – Regeneron Pharmaceuticals, Inc., Nektar Therapeutics and GlycoMimetics, Inc. (REGN-US, NKTR-US and GLYC-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.34 ... Read more (Read more...)

  • PULM: Business And Financial Update For Third Quarter 2017
    Zacks Small Cap Research5 months ago

    PULM: Business And Financial Update For Third Quarter 2017

    On November 9, 2017 Pulmatrix (PULM) announced their third quarter financial results and provided operational highlights. As a reminder, the global ABPA-asthma market is a multi-billion dollar opportunity with the U.S. representing close to two-thirds (~60%) of this industry.  Management expects the Phase I studies supporting the PUR1900 program in both CF and severe asthma patients to create partnership opportunities for both indications.

  • Is It Time To Buy Pulmatrix Inc (PULM)?
    Simply Wall St.6 months ago

    Is It Time To Buy Pulmatrix Inc (PULM)?

    Pulmatrix Inc (NASDAQ:PULM), a pharmaceuticals company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. As a small capRead More...

  • Is It The Right Time To Buy Pulmatrix Inc (PULM)?
    Simply Wall St.7 months ago

    Is It The Right Time To Buy Pulmatrix Inc (PULM)?

    Pulmatrix Inc (NASDAQ:PULM), a pharmaceuticals, biotechnology and life sciences company based in United States, saw a significant share price rise of over 20% in the past couple of months onRead More...

  • Zacks Small Cap Research7 months ago

    PULM: Influx Of Grant And Partnership Deal- Signs Of Growing Confidence In Pulmatrix

    We met with Pulmatrix’s (PULM) management (CFO  Bill Duke) at the Rodman & Renshaw conference held at New York city on September 11th and 12th 2017.  Mr. Duke spoke at length about advancing their two lead product candidates PUR1900 and PUR1800 through clinical studies. PUR1900 has been the subject of an Investigational New Drug application (IND).  Phase 1/1b is a critical milestone establishing PUR1900 safety, tolerability and PK profile versus ABPA-Asthma oral antifungal standard of care (Sporanox).  The clinical plan for Phase 1/1b PUR1900 is a three-part study comprised of single ascending dose (SAD), multiple ascending dose (MAD) as well as single dose comparing inhaled versus oral dose of the drug.  The studies will be conducted in parallel.  The SAD study will recruit six healthy volunteers who will be administered escalating doses of PUR1900 (dose: 5mg, 10mg and 25mg) to assess the safety and tolerability of PUR1900 along with 96h PK profile.  The MAD trail will also recruit six healthy volunteers to study the PK profile, safety and tolerability over a 14 day dosing period (10mg and 20mg).  Part 3 of the Phase 1/1b trial is a cross-over study designed to determine the PK, safety and tolerability of 20mg of PUR1900 (inhaled route) as compared to 200mg of Sporanox (oral route) in twelve asthma patients.

  • Benzinga8 months ago

    Vectura Announces Major New Tiotropium Bromide PI Development Programme Accelerated Through Licensing of Pulmatrix Technology

    Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading device and formulation business for inhaled airways products, today announces it is progressing the development ...

  • Zacks Small Cap Research9 months ago

    PULM: Pulmatrix Broadens Its Pulmonary Portfolio With Addition of In-Licensed Janssen Compound for COPD

    On June 13, 2017, Pulmatrix (PULM) announced the addition of a portfolio of novel inhaled narrow spectrum kinase inhibitor (NSKI) anti-inflammatories (PUR1800 and PUR5700) from RespiVert, a wholly owned subsidiary of Janssen Biotech, Inc.  Terms of the licensing agreement remain undisclosed.  The addition of PUR1800 and PUR5700 will expand the company’s pulmonary franchise to include treatments for COPD, IPF and asthma. As per the 2017 GOLD guidelines, COPD treatment commences with LAMA therapy (in group C) and treatment is escalated to ICS plus LABA therapy as necessary.

  • Zacks Small Cap Research11 months ago

    Zacks Initiates on Pulmatrix (NASDAQ:PULM)

    By  Anita Dushyanth, PhD NASDAQ:PULM Pulmatrix (NASDAQ:PULM) is a Lexington, MA based clinical stage biopharmaceutical company developing innovative inhaled products to address unmet medical needs in serious ...